Telix Pharmaceuticals
Update in progressTLX.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. It operates in three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Lead candidate TLX591 is in Phase 3 for advanced prostate cancer; other programs target kidney cancer, glioblastoma, bone marrow conditioning, and prostate cancer, plus PET imaging and diagnostic radiopharmaceuticals. Based in North Melbourne, 2015-founded, active globally with University Hospital Essen collaboration.
Company score
- Sentiment
- -0.15
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- -0.52
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!